{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:59:32Z","timestamp":1782572372445,"version":"3.54.5"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The 2022 revision of Japanese healthcare reimbursement removed pharmacists from the mandatory dysphagia team, despite emerging evidence of medication-related swallowing complications. Our previous pharmacovigilance analysis identified dopamine-blocking drugs as primary contributors to the risk of aspiration pneumonia. This study aimed to validate these findings through a clinical examination of pharmaceutical interventions performed by a multidisciplinary dysphagia team.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective observational study was conducted at a 97-bed community hospital in Osaka, Japan, from June 2023 to January 2024. All adult patients with suspected dysphagia who underwent a multidisciplinary team intervention were included in our analysis. Pharmaceutical intervention was requested when medication-related dysphagia or swallowing difficulties were suspected, with interventions classified into the following four categories: drug-induced dysphagia management, dosage form optimization, swallowing aid utilization, and medication burden reduction. Changes in the medication burden were analyzed using paired t-tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Among 59 patients with dysphagia (mean age, 81.1\u2009\u00b1\u20099.8\u00a0years; 33 males [55.9%], 26 females [44.1%]), 13 (22.0%) underwent pharmaceutical interventions. Drug-induced dysphagia management was the most common intervention (69.2%), targeting dopamine antagonists (sulpiride, risperidone, tiapride, and domperidone), benzodiazepines, and anticholinergics without dopamine-blocking effects. Suspected drug-induced dysphagia was the most common symptom among patients with dementia (38.9%). The intervention group showed a significant reduction in medication (mean, -3.2 medications; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), whereas the non-intervention group showed no change. Among the non-intervention group, potential opportunities for the optimization of angiotensin-converting enzyme inhibitors were identified in antihypertensive therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Pharmaceutical interventions may offer clinically meaningful contributions when utilized for patients with dysphagia, supporting the relevance of pharmacovigilance regarding the risks of dopamine antagonists. The findings of this study suggest the importance of reinstating pharmaceutical expertise to multidisciplinary dysphagia teams, as pharmacists provide clinically significant medication optimization, including identifying additional optimization opportunities through systematic medication reviews among vulnerable populations.\u00a0<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40780-025-00474-x","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T08:13:34Z","timestamp":1754381614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Contributions of pharmaceutical interventions to the multidisciplinary dysphagia team: A retrospective observational study"],"prefix":"10.1186","volume":"11","author":[{"given":"Akihito","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Obara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"474_CR1","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2147\/CIA.S107750","volume":"11","author":"LW Baijens","year":"2016","unstructured":"Baijens LW, Clav\u00e9 P, Cras P, Ekberg O, Forster A, Kolb GF, et al. European society for swallowing disorders \u2013 European Union Geriatric medicine society white paper: oropharyngeal dysphagia as a geriatric syndrome. Clin Interv Aging. 2016;11:1403\u201328. https:\/\/doi.org\/10.2147\/CIA.S107750.","journal-title":"Clin Interv Aging"},{"key":"474_CR2","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.3390\/jcm11092605","volume":"11","author":"TN Doan","year":"2022","unstructured":"Doan TN, Ho WC, Wang LH, Chang FC, Nhu NT, Chou LW. Prevalence and methods for assessment of oropharyngeal dysphagia in older adults: a systematic review and meta-analysis. J Clin Med. 2022;11: 2605. https:\/\/doi.org\/10.3390\/jcm11092605.","journal-title":"J Clin Med"},{"key":"474_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.pmr.2008.07.002","volume":"19","author":"M Baba","year":"2008","unstructured":"Baba M, Saitoh E, Okada S. Dysphagia rehabilitation in Japan. Phys Med Rehabil Clin N Am. 2008;19:929\u201338. https:\/\/doi.org\/10.1016\/j.pmr.2008.07.002.","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"474_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.resinv.2024.09.003","volume":"62","author":"A Ueda","year":"2024","unstructured":"Ueda A, Nohara K, Obara M, Watanabe S. Analysis of anticholinergic drugs associated with aspiration pneumonia using the Japanese adverse drug event report database: supplementary insights from a scoping review. Respir Investig. 2024;62:1044\u201350. https:\/\/doi.org\/10.1016\/j.resinv.2024.09.003.","journal-title":"Respir Investig"},{"key":"474_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/BF02266997","volume":"8","author":"B Stoschus","year":"1993","unstructured":"Stoschus B, Allescher H-D. Drug-induced dysphagia. Dysphagia. 1993;8:154\u20139. https:\/\/doi.org\/10.1007\/BF02266997.","journal-title":"Dysphagia"},{"key":"474_CR6","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","volume":"294","author":"LS Schneider","year":"2005","unstructured":"Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934\u201343. https:\/\/doi.org\/10.1001\/jama.294.15.1934.","journal-title":"JAMA"},{"key":"474_CR7","doi-asserted-by":"publisher","first-page":"E411","DOI":"10.1503\/cmaj.101406","volume":"183","author":"KF Huybrechts","year":"2011","unstructured":"Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA, Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ. 2011;183:E411\u20139. https:\/\/doi.org\/10.1503\/cmaj.101406.","journal-title":"CMAJ"},{"key":"474_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.2042-7158.1998.tb06876.x","volume":"50","author":"H Seager","year":"1998","unstructured":"Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375\u201382. https:\/\/doi.org\/10.1111\/j.2042-7158.1998.tb06876.x.","journal-title":"J Pharm Pharmacol"},{"key":"474_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5692\/clinicalneurol.49.90","volume":"49","author":"Y Umaki","year":"2009","unstructured":"Umaki Y, Nozaki S, Sugishita S, Shiimoto K, Hashiguchi S, Inui T, et al. Is an oral disintegrating tablets a formulation that is easy to ingest for patients experiencing difficulty with eating and swallowing? Rinsho Shinkeigaku. 2009;49:90\u20135. https:\/\/doi.org\/10.5692\/clinicalneurol.49.90.","journal-title":"Rinsho Shinkeigaku"},{"key":"474_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/S0140-6736(05)60114-6","volume":"352","author":"K Sekizawa","year":"1998","unstructured":"Sekizawa K, Matsui T, Nakagawa T, Nakayama K, Sasaki H. ACE inhibitors and pneumonia. Lancet. 1998;352:1069. https:\/\/doi.org\/10.1016\/S0140-6736(05)60114-6.","journal-title":"Lancet"},{"key":"474_CR11","doi-asserted-by":"publisher","first-page":"e4260","DOI":"10.1136\/bmj.e4260","volume":"345","author":"D Caldeira","year":"2012","unstructured":"Caldeira D, Alarc\u00e3o J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345: e4260. https:\/\/doi.org\/10.1136\/bmj.e4260.","journal-title":"BMJ"},{"key":"474_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.resinv.2021.09.012","volume":"60","author":"S Teramoto","year":"2022","unstructured":"Teramoto S. The current definition, epidemiology, animal models and a novel therapeutic strategy for aspiration pneumonia. Respir Investig. 2022;60:45\u201355. https:\/\/doi.org\/10.1016\/j.resinv.2021.09.012.","journal-title":"Respir Investig"},{"key":"474_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/j.1447-0594.2012.00868.x","volume":"12","author":"T Kojima","year":"2012","unstructured":"Kojima T, Akishita M, Kameyama Y, Yamaguchi K, Yamamoto H, Eto M, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int. 2012;12:761\u20132. https:\/\/doi.org\/10.1111\/j.1447-0594.2012.00868.x.","journal-title":"Geriatr Gerontol Int"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-025-00474-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-025-00474-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:03:28Z","timestamp":1754427808000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-025-00474-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1186\/s40780-025-00474-x","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Ethics Committee of Teikyo Heisei University (approval no.: 2024\u2013129) and was conducted in accordance with the Declaration of Helsinki. The requirement for written informed consent was waived owing to the retrospective nature of the study and the use of anonymized data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}